Published in Am J Cancer Res on August 08, 2011
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852) | NCT01174238
Study of Temzolomide and Gleevec in Advanced Melanoma | NCT00667953
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res (2012) 0.92
Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One (2013) 0.87
Antitumor activity of placenta-derived mesenchymal stem cells producing pigment epithelium-derived factor in a mouse melanoma model. Oncol Lett (2012) 0.86
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun (2016) 0.81
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget (2015) 0.80
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget (2015) 0.80
Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. Oncol Lett (2013) 0.79
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget (2015) 0.76
Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades. Oncoimmunology (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol (2003) 12.96
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 7.22
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev (2002) 5.15
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) (1999) 4.85
The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol (2005) 4.54
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer (2003) 3.93
Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol (2001) 3.84
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol (2002) 3.49
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res (2005) 3.38
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res (2002) 3.19
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res (2004) 3.03
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol (2003) 2.81
Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol (1999) 2.79
The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol (1988) 2.53
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer (2010) 2.51
MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol (2004) 2.45
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res (2008) 2.33
The role of neuropilins in cancer. Mol Cancer Ther (2006) 2.28
Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine (2000) 2.25
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res (2001) 1.99
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene (2000) 1.96
Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol (2002) 1.95
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90
Endogenous angiogenesis inhibitors. APMIS (2004) 1.89
Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J (2001) 1.86
Matrix metalloproteinases in human melanoma. J Invest Dermatol (2000) 1.84
Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol (2010) 1.84
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res (2001) 1.80
Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J (1995) 1.76
Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer (2007) 1.75
Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res (2009) 1.52
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene (2003) 1.48
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther (2010) 1.45
Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer (1999) 1.38
Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun (1993) 1.38
Endogenous inhibitors of angiogenesis: a historical review. Leuk Res (2008) 1.34
Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood (2004) 1.33
Vasculogenic mimicry: current status and future prospects. Cancer Lett (2007) 1.32
Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31
Regulation of microvascular permeability by vascular endothelial growth factors. J Anat (2002) 1.30
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol (1994) 1.27
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res (2002) 1.27
Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis (2000) 1.27
Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta (2009) 1.24
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 1.24
Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol (1997) 1.23
Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation (2009) 1.22
Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol (2001) 1.19
A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One (2010) 1.17
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res (1997) 1.17
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16
Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg (2002) 1.15
Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer (2007) 1.15
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer (2010) 1.15
Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol (2002) 1.12
A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol (1996) 1.12
Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res (1999) 1.11
Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol (1995) 1.08
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08
Molecular regulation of angiogenesis in the skin. J Invest Dermatol (1996) 1.06
Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol (2004) 1.06
Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol (1999) 1.05
Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res (2002) 1.05
The "dermal cage": a modification of the inferior pedicle breast reduction. Aesthetic Plast Surg (2013) 0.79